Effects of heparin on platelet aggregation and release and thromboxane A2 production
- PMID: 7258300
- PMCID: PMC1903756
Effects of heparin on platelet aggregation and release and thromboxane A2 production
Abstract
Heparin, when added to citrated platelet-rich plasma (PRP), caused potentiation of platelet aggregation and the release reaction induced by the aggregating agents adenosine diphosphate (ADP), arachidonic acid, collagen, and epinephrine. At low concentrations (4.7 x 10(-5) M) arachidonic acid failed to cause aggregation of platelets in citrated PRP. However, in the presence of heparin, the same concentration of arachidonic acid caused aggregation. Examination of PRP for the presence of thromboxane A2 (TxA2) by use of a bioassay revealed that heparin also stimulated release of TxA2. This finding indicated that platelets released more TxA2 when they were challenged by low concentrations of arachidonic acid in the presence of heparin than in its absence. Platelets were labeled with 3H-arachidonic acid and 14C-serotonin, and attempts were made to determine whether heparin stimulated the platelet release reaction first with subsequent increased production of TxA2, or alternatively, whether heparin stimulated TxA2 production first with subsequent enhancement of the release reaction. In view of the demonstrated simultaneous release of 14C-serotonin and 3H-arachidonic acid metabolites, it appeared that either release of 14C and 3H occurs concurrently or, even if one of these events is dependent on the other, both events take place in rapid succession. Timed sequential studies revealed that in the presence of arachidonic acid, the addition of heparin hastened the apparently simultaneous release of both 14C and 3H.
Similar articles
-
Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.Thromb Res. 1984 Feb 1;33(3):277-88. doi: 10.1016/0049-3848(84)90163-4. Thromb Res. 1984. PMID: 6424261
-
Abnormalities of aggregation, thromboxane A2 synthesis, and 14C serotonin release in platelets of patients with idiopathic scoliosis.Spine (Phila Pa 1976). 1983 Apr;8(3):236-41. doi: 10.1097/00007632-198304000-00003. Spine (Phila Pa 1976). 1983. PMID: 6623192
-
[Effect of heparin on platelet aggregation in vitro].Folia Haematol Int Mag Klin Morphol Blutforsch. 1984;111(6):735-49. Folia Haematol Int Mag Klin Morphol Blutforsch. 1984. PMID: 6083949 German.
-
Role of thromboxane A2.Adv Exp Med Biol. 1985;192:293-308. doi: 10.1007/978-1-4615-9442-0_21. Adv Exp Med Biol. 1985. PMID: 2939695 Review. No abstract available.
-
Effect of heparin and heparin fractions on platelet aggregation.J Clin Invest. 1980 Jan;65(1):64-73. doi: 10.1172/JCI109661. J Clin Invest. 1980. PMID: 6243142 Free PMC article. Review.
Cited by
-
[Thromboxane concentrations in the arterial blood of cigarette smokers].Klin Wochenschr. 1986 Jul 15;64(14):648-52. doi: 10.1007/BF01726917. Klin Wochenschr. 1986. PMID: 3762015 German.
-
Effect of dexamethasone on in vivo prostanoid production in the rabbit.J Clin Invest. 1984 Jul;74(1):120-3. doi: 10.1172/JCI111391. J Clin Invest. 1984. PMID: 6429194 Free PMC article.
-
Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.Front Pharmacol. 2022 Jul 22;13:938552. doi: 10.3389/fphar.2022.938552. eCollection 2022. Front Pharmacol. 2022. PMID: 35935872 Free PMC article.
-
Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.Br J Clin Pharmacol. 1984 Jan;17(1):43-8. doi: 10.1111/j.1365-2125.1984.tb04997.x. Br J Clin Pharmacol. 1984. PMID: 6197984 Free PMC article.
-
The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target.RSC Adv. 2019 Jan 23;9(6):3020-3029. doi: 10.1039/c8ra09724k. eCollection 2019 Jan 22. RSC Adv. 2019. PMID: 35518950 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials